INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
TS
Corporate insider

Tyagarajan Seshu

Chief Technology OfficerCIK 0001923794

EDGAR filingsOpen in network
Disclosed transactions2
Buys / sells0 / 2
Max Insider Score17
Connections with evidence1

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
8
TS
Tyagarajan SeshuChief Technology Officer
CADLCandel Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$84K
7,000 sh
Aug 17, 2026Aug 19, 2026
traded Aug 17, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Candel Therapeutics, Inc.Chief Technology Officer · Jul 1, 2026
17
TS
Tyagarajan SeshuChief Technology Officer
CADLCandel Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL
$70K
7,000 sh
Jun 29, 2026
Jul 1, 2026
traded Jun 29, 2026
+2d
SEC FORM 4

Evidence